Press release
Propulsion of Peripheral Neuropathic Pain Clinical Trial Pipeline as Novel and Extensive 10+ Therapies Likely to Enter in the Domain | DelveInsight
Peripheral Neuropathic Pain Pipeline
In the Peripheral Neuropathic Pain pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Peripheral Neuropathic Pain NDA approvals (if any), and product development activities comprising the technology, Peripheral Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Peripheral Neuropathic Pain Pipeline treatment landscape of the report, click here @ Peripheral Neuropathic Pain Pipeline Outlook- https://www.delveinsight.com/report-store/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Peripheral Neuropathic Pain Pipeline Report
• DelveInsight's Peripheral Neuropathic Pain Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading companies working in the Peripheral Neuropathic Pain Market include Haisco Pharmaceutical Group, AlzeCure, Eli Lilly and Company, Bayer, Eliem Therapeutics, SIMR Biotech, Aptinyx, Lexicon Pharmaceuticals, and others.
• Promising Peripheral Neuropathic Pain pipeline therapies in the various stages of development include Duloxetine, Pregabalin, DS-5565, RGH-896, Pregabalin, and others.
• On March 2023, AlzeCure Pharma announced a study of phase 2 clinical trials for ACD440 Gel 14mg/g. This is a double-blind, randomized, placebo-controlled crossover outpatient study in patients with peripheral neuropathic pain with allodynia or hyperalgesia to cold, heat, brush and/ or pinprick stimulation. Patients will in random order receive ACD440 Gel or placebo treatment twice daily for 7 days, topically applied to the painful area. This is followed by a 2-week washout period, then receive the alternate treatment.
• On May 2023, Eliem Therapeutics (UK) Ltd announced a study of phase 2 clinical trials for ETX-018810. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.
Peripheral Neuropathic Pain Overview
Neuropathic pain is defined by the International Association for the Study of Pain as pain caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain (NP) is not a particular disease, but the clinical condition that is caused by a variety of different diseases and lesions, injuring the nervous system at peripheral or central level, resulting in peripheral NP or central NP, respectively.
For further information, refer to the detailed Peripheral Neuropathic Pain Unmet Needs, click here for Peripheral Neuropathic Pain Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Peripheral Neuropathic Pain Emerging Drugs Profile
• HSK 16149: Haisco Pharmaceutical Group
• ACD 440: AlzeCure
Peripheral Neuropathic Pain Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Peripheral Neuropathic Pain. The companies which have their Peripheral Neuropathic Pain drug candidates in the most advanced stage, i.e. phase II/III include, Haisco Pharmaceutical Group.
Request a sample and discover the recent advances in Peripheral Neuropathic Pain Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Peripheral Neuropathic Pain Segmentation- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Peripheral Neuropathic Pain Drugs and Companies
• Duloxetine: Eli Lilly and Company
• Pregabalin: Shionogi
• DS-5565: Daiichi Sankyo Co. Ltd.
Peripheral Neuropathic Pain Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Peripheral Neuropathic Pain Therapeutics Market include-
Haisco Pharmaceutical Group, AlzeCure, Eli Lilly and Company, Bayer, Eliem Therapeutics, SIMR Biotech, Aptinyx, Lexicon Pharmaceuticals, and others.
Dive deep into rich insights for drugs for Peripheral Neuropathic Pain Pipeline, click here @ Peripheral Neuropathic Pain Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Peripheral Neuropathic Pain Pipeline Report
• Coverage- Global
• Companies- Haisco Pharmaceutical Group, AlzeCure, Eli Lilly and Company, Bayer, Eliem Therapeutics, SIMR Biotech, Aptinyx, Lexicon Pharmaceuticals, and others.
• Therapies- Duloxetine, Pregabalin, DS-5565, RGH-896, Pregabalin, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Peripheral Neuropathic Pain Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Peripheral Neuropathic Pain: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peripheral Neuropathic Pain- DelveInsight's Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase II/ III)
11. HSK 16149: Haisco Pharmaceutical Group
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. ACD 440: AlzeCure
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Peripheral Neuropathic Pain Key Companies
21. Peripheral Neuropathic Pain Key Products
22. Peripheral Neuropathic Pain - Unmet Needs
23. Peripheral Neuropathic Pain - Market Drivers and Barriers
24. Peripheral Neuropathic Pain - Future Perspectives and Conclusion
25. Peripheral Neuropathic Pain Analyst Views
26. Peripheral Neuropathic Pain Key Companies
27. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Propulsion of Peripheral Neuropathic Pain Clinical Trial Pipeline as Novel and Extensive 10+ Therapies Likely to Enter in the Domain | DelveInsight here
News-ID: 3181970 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Neuropathic
Neuropathic Pain Management Market Size Analysis by Application, Type, and Regio …
USA, New Jersey- According to Market Research Intellect, the global Neuropathic Pain Management market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period.
The neuropathic pain management market is experiencing consistent growth due to rising incidences of chronic conditions such as diabetes, cancer, and neurological disorders, which…
Neuropathic Pain Market New Therapeutic Developments and Treatments
On April 08, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Neuropathic Pain Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across…
Neuropathic Pain Market: Innovative Therapies Reshaping Chronic Pain Management
In recent years, the global Neuropathic Pain Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Neuropathic Pain Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including…
The increase in Neuropathic Ocular Pain Market Size is a direct consequence of i …
As per DelveInsight, the Neuropathic Ocular Pain Market is anticipated to grow in the coming years owing to the rise in the number of prevalent cases in the 7MM, the improvement in the research and development activities, and the launch of novel therapies in the Neuropathic Ocular Pain market. There are several key players involved in developing therapies for Neuropathic Ocular Pain, like Novartis, and others.
The Neuropathic Ocular Pain market…
Neuropathic Pain Market Growth Factors and Manufacturers
Neuropathic Pain Market 2022
Global Neuropathic Pain Market to Reach US$ 8.3 Bn by 2024 End.
Machine learning and artificial intelligence have been transforming the healthcare vertical since the last few years. AI-powered healthcare solutions are there to help the patients with automation of routine tasks and data analysis. Wearable technologies are a part of exclusive physiotherapy devices that are capable of tracking and analyzing specific movements of the patients. This would…
Global Neuropathic Pain Market Research Report Forecast to 2023
Neuropathic Pain Market 2020 comprises a detailed survey of the Neuropathic Pain Market size, share, trends, extension, consumption, and share, segments, application and Forecast 2025.
Global "Neuropathic Pain" Market 2020-2025 Report contains all demographic as well as analytical data regarding market review, growth, demand, and budget analysis. The report mainly highlights the significant trends of the Neuropathic Pain market in terms of thriving companies, business methods, product values and pricing, revenue,…
